2023
DOI: 10.1002/ajmg.a.63428
|View full text |Cite
|
Sign up to set email alerts
|

Epilepsy in cardiofaciocutaneous syndrome: Clinical burden and response to anti‐seizure medication

Daniel L. Kenney‐Jung,
Josue E. Collazo‐Lopez,
Dante J. Rogers
et al.

Abstract: Treatment‐resistant epilepsy is among the most serious complications of cardiofaciocutaneous syndrome (CFCS), a rare disorder caused by germline variants in the RAS‐MAPK signaling pathway. This study analyzed the clinical characteristics of epilepsy and response to anti‐seizure medications (ASMs) in a multinational CFCS cohort. A caregiver survey provided data regarding seizure history, use of ASMs and other treatment approaches, adverse effects, caregiver perception of treatment response, and neurological dis… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

1
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 31 publications
1
0
0
Order By: Relevance
“…In particular, the patient’s seizures responded well to LCM, which has a minimal risk of drug interactions, and is safe and effective. This finding is consistent with a recent publication showing relatively high efficacy scores of sodium-channel blockers in CFC ( Kenney-Jung et al, 2024 ). Our patient experienced DIHS, an adverse drug reaction commonly associated with aromatic antiseizure drugs in Japanese patients, such as PB and carbamazepine ( Hama et al, 2022 ).…”
Section: Discussionsupporting
confidence: 93%
“…In particular, the patient’s seizures responded well to LCM, which has a minimal risk of drug interactions, and is safe and effective. This finding is consistent with a recent publication showing relatively high efficacy scores of sodium-channel blockers in CFC ( Kenney-Jung et al, 2024 ). Our patient experienced DIHS, an adverse drug reaction commonly associated with aromatic antiseizure drugs in Japanese patients, such as PB and carbamazepine ( Hama et al, 2022 ).…”
Section: Discussionsupporting
confidence: 93%